InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.053 -0.327 (-86.05%)+
Announcement
Release
6 Feb 2026 8:19AM
Price at Release
$0.380
Full Release
download
Summary
Immutep Limited announced that it has reached 50% enrolment in its global TACTI-004 Phase III trial, which is evaluating eftilagimod alfa (efti) in combination with KEYTRUDA® and chemotherapy as a first-line therapy for advanced/metastatic non-small cell lung cancer (1L NSCLC). The trial has enrolled 378 patients worldwide and aims to complete enrolment by the third quarter of 2026. Efti is a novel MHC Class II agonist designed to enhance the immune response in cancer treatment. The combination therapy could potentially establish a new standard of care for 1L NSCLC by improving responses across all PD-L1 expression levels. Immutep is progressing with its clinical milestones, including conducting a futility analysis in the first quarter of 2026.
Key Points
  • Immutep achieves 50% enrolment in TACTI-004 Phase III trial.
  • Trial evaluates eftilagimod alfa (efti) with KEYTRUDA® and chemotherapy.
  • Enrolment target is 756 patients globally for advanced/metastatic 1L NSCLC.
  • Combination therapy aims to improve response across all PD-L1 expression levels.
  • Futility analysis expected in Q1 2026, full enrolment by Q3 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.